Actinic Keratosis Market

Market Insights

Actinic keratosis (AK) or solar keratosis are keratotic papules, macules, and plaques arising from the intraepidermal proliferation of keratinocytes due to exposure to ultraviolet radiation. Although AKs and squamous cell carcinoma progression are rare, AKs still pose a concern because most cutaneous squamous cell carcinomas result from pre-existing AKs. Due to this, clinicians recommend routine treatment of AKs. This report studies the current and prospects of the global actinic keratosis treatment market.

For this report, the global actinic keratosis market is studied in terms of treatment type and geographical distribution. Based on treatment type, this market is segmented into destructive treatment (liquid nitrogen cryotherapy, surgical therapy), photodynamic therapy (5-aminolevulinic acid, methyl aminolevulinate), topical medications (5-fluorouracil, imiquimod, ingenolmebutate, diclofenac sodium), and chemical peels and dermabrasion. The market size and forecast for each considered segment are provided for 2014–2022, along with their respective CAGRs (value %) for the forecast durationof22016–2022t.

Geographically, the global actinic keratosis market is studied for the following regional and country-level markets:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Russia
  • Rest of Europe
• Asia-Pacific
  • India
  • China
  • Japan
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Each country-level market (and Middle East, Africa, and Latin America markets) thus covered in the report includes the cumulative market size and forecast of destructive treatment, photodynamic therapy, topical medications, chemical peels, and others. In addition, since photodynamic therapy has opened further avenues for effective AK treatment, this section also presents the exclusive market size and forecast for the 5-aminolevulinic acid (ALA) and methyl aminolevulinate (MAL) segments for the country-level and Middle East, Africa, and Latin America markets. The market size and forecast, along with growth rates, are provided for the periods 2014–2022 and 2016–2022, respectively.

Along with quantitative presentations, this report also includes an analysis of market environment factors such as drivers, restraints, and opportunities that determine the overall trends in the actinic keratosis market. Competition assessment tools such as attractive investment propositions, market competitive analysis by key players, and market inclination insights are also incorporated in this study. This report concludes with a profile of major companies active in the development, manufacturing, and sale of AK treatments. Such profiling is done based on the business description, financial health, product portfolio, and news coverage of such players.

Based on treatment types, the global actinic keratosis market is categorized into:

Destructive Treatment

• Liquid Nitrogen Cryotherapy
• Surgical Therapy

Photodynamic Therapy

• 5-aminolevulinic acid (ALA)
• Methyl aminolevulinate (MAL)

Topical Medications

• 5-fluorouracil (5-FU)
• Imiquimod
• Ingenolmebutate
• Diclofenac Sodium
• Chemical Peel and Others

In 2015, destructive treatments accounted for the largest share of the overall actinic keratosis market. Based on their proven efficiency and cost-effectiveness, cryotherapy and surgical methods are considered the gold standard for AK treatment worldwide. Cryosurgery is the largest segment across all the available treatment methods and takes over 50% of the destructive treatment market. Laser treatments such as carbon dioxide and erbium:yttrium:aluminum: garnet are also increasingly preferred by clinicians due to their effectiveness and aesthetic appeal. Topical medications constitute a prolonged treatment regimen and play a key role in AK treatment; however, patient compliance is a key issue that holds back the growth of this segment. Yet, cheaper treatment costs favor the stability of these topical medications, particularly in the middle- and low-income markets. Photodynamic therapy is the fastest-growing segment through the forecast period due to the growing demand for non-invasive treatments and the aesthetic appeal of photodynamic therapy.

North America is the largest market for actinic keratosis treatments due to the growing prevalence of AK and high public awareness about the prevention and management of skin cancer. In 2015, the U.S. held the largest share in the global actinic keratosis market, owing to the high prevalence of AK in the country, supplemented by favorable reimbursements for AK treatment. Asia-Pacific is the fastest-progressing regional market for AK treatments. Australia has the highest prevalence of actinic keratosis, with a range between 40% and 50% in adults.

Growing awareness in a potential population group, improving healthcare infrastructure, and healthcare expenditure are this market’s key drivers. Japan is also actively expanding the market for actinic keratosis treatment in terms of revenue. Japan as a market is probably 2-3 years behind Europe in developing actinic keratosis.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Actinic Keratosis Market Revenue, by Treatment, 2015, (US$ Mn)
2.2 Global Actinic Keratosis Market Revenue, by Geography, 2015, (USD Million)

Chapter 3 Market Overview
3.1 Introduction and Market Definition
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 High Prevalence of Actinic Keratosis and Subsequent Risk of Developing Malignancies
3.3.2 Restraints
3.3.2.1 Non-adherence to Treatments
3.3.3 Market Opportunities
3.3.3.1 Lucrative future for Light-based Treatments
3.4 Attractive Investment Proposition
3.5 Market Competition Assessment Key Players: Global Actinic Keratosis Market

Chapter 4 Global Actinic Keratosis Market, by Treatments
4.1 Preface
4.2 Destructive Treatment
4.2.1 Liquid Nitrogen Cryotherapy
4.2.2 Surgical Therapy
4.3 Photodynamic Therapy
4.3.1 5-aminolevulinic acid (ALA)
4.3.2 Methyl Aminolevulinate (MAL)
4.4 Topical Medications
4.4.1 5-fluorouracil [5-FU]
4.4.2 Imiquimod
4.4.3 Ingenol Mebutate
4.4.4 Diclofenac Sodium
4.5 Chemical Peels and Dermabrasion

Chapter 5 Global Actinic Keratosis Market, by Geography
5.1 Preface
5.2 North America
5.3 Europe
5.4 Asia Pacific
5.5 Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 Tolmar Pharmaceuticals, Inc.
6.1.1 Tolmar Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.2 DUSA Pharmaceuticals, Inc. (Sun Pharma)
6.2.1 DUSA Pharmaceuticals, Inc. (Sun Pharma): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.3 Valeant Pharmaceuticals International, Inc.
6.3.1 Valeant Pharmaceuticals International, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.4 Aqua Pharmaceuticals, LLC
6.4.1 Aqua Pharmaceuticals, LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.5 Galderma S.A.
6.5.1 Galderma S.A.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.6 Perrigo Company plc,
6.6.1 Perrigo Company plc,: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.7 Apotex, Inc.
6.7.1 Apotex, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.8 LEO Laboratories Ltd. (LEO Pharma A/S)
6.8.1 LEO Laboratories Ltd. (LEO Pharma A/S): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List of Figures

FIG. 1 Actinic Keratosis Treatment Market: Research Methodology
FIG. 2 Global Actinic Keratosis Market Revenue, by Treatment, 2015 (USD Mn)
FIG. 3 Global Actinic Keratosis Market Revenue, by Geography, 2015 (Value %)
FIG. 4 Risk Factors Associated with Development of Actinic Keratosis
FIG. 5 Attractive Investment Proposition: Global Actinic Keratosis Market
FIG. 6 Top 3 Countries: Global Destructive Treatment Market for Actinic Keratosis Treatment, 2014 to 2022 (USD Mn)
FIG. 7 Liquid Nitrogen Cryotherapy Market, 2014 – 2022 (US$ Mn)
FIG. 8 Surgical Therapies Market, 2014 – 2022 (US$ Mn)
FIG. 9 Top 3 Countries: Global Photodynamic Therapy Market for Actinic Keratosis Treatment, 2014 to 2022 (USD Mn)
FIG. 10 5-aminolevulinic acid (ALA) Market, 2014 – 2022 (US$ Mn)
FIG. 11 Methyl aminolevulinate (MAL)Market, 2014 – 2022 (US$ Mn)
FIG. 12 Top 3 Countries: Global Topical Medications Market for Actinic Keratosis Treatment, 2014 to 2022 (USD Mn)
FIG. 13 5-fluorouracil (5-FU) Market, 2014 – 2022 (US$ Mn)
FIG. 14 Imiquimod Market, 2014 – 2022 (US$ Mn)
FIG. 15 Ingenol Mebutate Market, 2014 – 2022 (US$ Mn)
FIG. 16 Diclofenac Sodium Market, 2014 – 2022 (US$ Mn)
FIG. 17 Chemical Peels and Dermabrasion Market, 2014 – 2022 (US$ Mn)
FIG. 18 Top 3 Countries: Global Chemical Peels & Dermabrasion Market for Actinic Keratosis Treatment, 2014 to 2022 (USD Mn)

List of Tables

TABLE 1 Global Actinic Keratosis Market, by Treatment, 2013-2022 (USD Million)
TABLE 2 Global Destructive Treatment Market, by Type, 2014-2022 (USD Million)
TABLE 3 Global Photodynamic Therapy Market, by Products, 2014-2022 (USD Million)
TABLE 4 Global Topical Medications Market, by Products, 2014-2022 (USD Million)
TABLE 5 Global Actinic Keratosis Market, by Geography, 2014-2022 (USD Million)
TABLE 6 North America Actinic Keratosis Market, by Geography, 2014-2022 (USD Million)
TABLE 7 U.S. Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 8 U.S. Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 9 Canada Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 10 Canada Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 11 Europe Actinic Keratosis Market, by Geography, 2014-2022 (USD Million)
TABLE 12 U.K. Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 13 U.K. Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 14 Germany Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 15 Germany Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 16 France Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 17 France Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 18 Spain Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 19 Spain Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 20 Italy Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 21 Italy Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 22 Rest of Europe Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 23 Rest of Europe Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 24 Asia Pacific Actinic Keratosis Market, by Geography, 2014-2022 (USD Million)
TABLE 25 Japan Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 26 Japan Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 27 China Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 28 China Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 29 Australia Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 30 Australia Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 31 Rest of APAC Actinic Keratosis Market, by Treatment, 2014-2022 (USD Million)
TABLE 32 Rest of APAC Photodynamic Therapy Market, by Type, 2014-2022 (USD Million)
TABLE 33 Latin America Actinic Keratosis Market, by Treatment, 2015 – 2022 (USD Mn)
TABLE 34 Latin America Photodynamic Therapy Market, by Type, 2015 – 2022 (USD Mn)
TABLE 35 Middle East and Africa Actinic Keratosis Market, by Treatment, 2015 – 2022 (USD Mn)
TABLE 36 Middle East and Africa Photodynamic Therapy Market, by Type, 2015 – 2022 (USD Mn)
TABLE 37 Tolmar Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 38 DUSA Pharmaceuticals, Inc. (Sun Pharma): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 39 Valeant Pharmaceuticals International, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 40 Aqua Pharmaceuticals,LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 41 Galderma S.A.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 42 Perrigo Company plc,: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 43 Apotex, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 44 LEO Laboratories Ltd. (LEO Pharma A/S): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)